Update on proposal to move to one funded brand of lamotrigine (Logem)
After reviewing the feedback on the consultation letter of 29 August 2018 to move to one funded brand of lamotrigine (Logem), we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.
PHARMAC would like to thank everyone who provided feedback on a proposal to move to one funded brand of lamotrigine (Logem).
This was the subject of a consultation letter dated 29 August 2018, with a closing date for feedback of 26 September 2018.
After reviewing the feedback, we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.
This means that a decision will not be made in time to implement the proposal from 1 December 2018, as proposed in the consultation. At this stage we do not have a firm timeframe for when a decision will be made.
If you have any questions about this update, please contact procurement@pharmac.govt.nz.